STZ - Constellation Brands, Inc.

NYSE - NYSE Delayed Price. Currency in USD
189.95
-0.91 (-0.48%)
At close: 4:05PM EST
Stock chart is not supported by your current browser
Previous Close190.86
Open191.12
Bid189.65 x 900
Ask189.90 x 1100
Day's Range189.67 - 193.38
52 Week Range163.47 - 214.48
Volume1,787,869
Avg. Volume1,193,859
Market Cap36.425B
Beta (5Y Monthly)0.65
PE Ratio (TTM)44.05
EPS (TTM)4.31
Earnings DateApr 01, 2020 - Apr 05, 2020
Forward Dividend & Yield3.00 (1.58%)
Ex-Dividend DateFeb 08, 2020
1y Target Est225.00
  • Altria Focuses on Pricing & RRPs Amid Low Cigarette Volumes
    Zacks

    Altria Focuses on Pricing & RRPs Amid Low Cigarette Volumes

    Altria's (MO) expansion in RRPs and focus on pricing bode well amid declining cigarette shipment volumes.

  • Moody's

    Constellation Brands, Inc. -- Moody's announces completion of a periodic review of ratings of Constellation Brands, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Constellation Brands, Inc. New York, January 17, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Constellation Brands, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Coca-Cola Adds Two Powerade Sports Drinks, Enhances Portfolio
    Zacks

    Coca-Cola Adds Two Powerade Sports Drinks, Enhances Portfolio

    Coca-Cola (KO) launches Powerade Ultra and Powerade Power Water under Powerade Sports drink category. This is likely to aid the company's sales.

  • How Long Can the Rally in Canopy Growth Stock Last?
    InvestorPlace

    How Long Can the Rally in Canopy Growth Stock Last?

    Cannabis stocks performed terribly in 2019, and Canopy Growth (NYSE:CGC) was no exception. Despite the backing -- to the tune of $4 billion -- of Constellation Brands (NYSE:STZ), and over a full year of legal cannabis sales in Canada, CGC has yet to turn a profit. With investors souring on the cannabis industry in general, Canopy Growth stock lost 23% of its value in 2019. That number is actually misleading because CGC went into 2019 just as it was beginning to recover from a slump. It actually closed the year down a whopping 52% from its high at the end of April. So it is big news that CGC has strung together multiple days of significant growth. After a 4.4% pop on Wednesday, that's 21% in just three days.Source: Shutterstock What is going on with Canopy Growth? And more importantly for investors, can it sustain this rally to the point of a full-blown recovery? Why the Sudden Optimism Around Cannabis Stocks?This week has been an anomaly if you've been following cannabis stocks. For much of 2019, the story was rather grim. However, this week has seen many of them pop. CGC is up 21% since Monday. Hexo (NYSE:HEXO) is up 38%. Aurora Cannabis (NYSE:ACB) is up 25%. Cronos (NASDAQ:CRON) is up 23%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsEven lowly CannTrust (NYSE:CTST) has seen an 11% gain.There seem to be two factors that have lit a fire under these stocks this week. The first is the news that the first edibles under Canada's "Cannabis 2.0" rollout hit stores. The second is the introduction of a bipartisan bill in the U.S. that would bypass Food and Drug Administration restrictions and legalize hemp-derived CBD nationally for use in foods and supplements in the American market. What If Cannabis 2.0 Also Stumbles?Having Congress take action to eliminate the confusion over CBD sales in the U.S. will undoubtedly help cannabis producers. Many of them already sell CBD products in that market (the FDA hasn't been enforcing its ban), but legalization would likely provide at least a modest boost to sales. * 7 Earnings Reports to Watch Next Week The bigger issue for most cannabis stocks is the Cannabis 2.0 rollout in Canada. What happens if it also stumbles the way the initial legal recreational marijuana launch did? After all, that disaster was the reason so many cannabis stocks went through the roof in 2018 (in anticipation) and then tanked as reality hit. Unfortunately Cannabis 2.0 got off to a rocky start, with a lengthy waiting period between legalization of edibles and when companies could actually sell them. Even with edibles and cannabis-infused drinks now available (nearly a month after legalization), there are once again shortages in stores. Ontario -- by far the country's largest market -- remains critically underserved, with a fraction of the expected retail locations open. Canada's second-largest province played spoiler by announcing a ban on the sale of most cannabis edibles. Despite legalization at the federal level, Quebec is concerned that sweetened cannabis products would appeal to minors. Consumers are balking at the price of what edibles are available.Adding to the industry woes, legal recreational marijuana sales across Canada were dropping through the fall.The industry pinned a lot of hopes on Cannabis 2.0 being the point where the legal marijuana market in Canada found its legs. Instead, it's showing all the signs of being a repeat of last year. Bottom Line: Canopy Growth Stock Remains a Risky BetAt under $25, CGC can be a tempting investment. Twice in the past year and a half, the stock has been trading in the $50 range. The company has a new CEO in place, the backing of a multinational beverage conglomerate, and Canada's Cannabis 2.0 market has launched. After being beaten down for virtually eight straight months, CGC just strung together three straight days of gains for an impressive 21% boost. * The 10 Best Value Stocks to Own in 2020 Unfortunately, many of the challenges that caused Canopy Growth and other cannabis stocks to perform so poorly last year remain, especially in the Canadian market. There has been some optimism to start 2020 because of the edibles launch and the promise that Ontario will open more recreational cannabis stores, but that may not be enough. The investment analysts polled by CNN Business rate Canopy Growth stock as a "hold," and their median 12-month price target of just $19.77 represents 20.6% downside. Of the 21 analysts, the most optimistic has a $25.28 price target. Maybe they're all wrong. Maybe 2020 will be the year the legal recreational marijuana market takes off in Canada, powering cannabis stocks to a recovery. But I wouldn't bet on it.As of this writing, Brad Moon did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 5 Dow Jones Stocks to Buy for 2020 * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure * 3 Tech Stocks to Play Ahead of Earnings The post How Long Can the Rally in Canopy Growth Stock Last? appeared first on InvestorPlace.

  • Thomson Reuters StreetEvents

    Edited Transcript of STZ earnings conference call or presentation 8-Jan-20 3:30pm GMT

    Q3 2020 Constellation Brands Inc Earnings Call

  • 4 Marijuana Stocks to Buy for the Big 2020 Rebound
    InvestorPlace

    4 Marijuana Stocks to Buy for the Big 2020 Rebound

    You hear that? That's the sound of the beginning of a big rebound in marijuana stocks. Year-to-date, the ETFMG Alternative Harvest ETF (NYSEARCA:MJ) is already up almost 10% -- and we are less than three weeks into the year. That's a huge gain in a short amount of time.The big rebound in pot stocks can be attributed to favorable fundamental developments (multiple cannabis companies have reported strong fourth quarter numbers in early January), favorable legal developments (among other things, Illinois just legalized recreational marijuana), and a whole bunch of investors deciding that with the new year, comes new opportunity.That's the good news for cannabis bulls. The better news? This big rebound in marijuana stocks is just getting started.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOver the next several quarters, everything is going to improve for the cannabis sector. Demand trends will re-accelerate thanks to new vapes and edibles products, as well as retail footprint expansion. Supply overhang issues will ease with rebounding demand. International markets will start to take off as governments around the world follow in Canada's footsteps. Revenue growth trends will improve. Margins will bounce back. Losses will narrow.All in all, things will just get better for the cannabis sector in 2020, and as they do, depressed and beaten-up pot stocks will rebound. * The Top 5 Dow Jones Stocks to Buy for 2020 With that in mind, let's take a deeper look at four marijuana stocks to buy for the big 2020 rebound. Canopy Growth (CGC)Source: Shutterstock The cannabis market's biggest and most important company, Canopy Growth (NYSE:CGC), has been leading the pot stock rebound in 2020 so far. Year-to-date, CGC stock is up more than 15%.Canopy will continue to be a leader in this rebound for the rest of 2020 for one very simple reason: this is the best cannabis company out there by a mile.They have the biggest balance sheet -- thanks to a multi-billion dollar investment from Constellation Brands (NYSE:STZ) -- with the most resources and firepower to invest in things like product development, international expansion, strategic acquisitions, and production build-out. They also have the biggest sales base, the most production capacity, and the widest global distribution network.The management team is arguably the best in the business, as Constellation has infused the company with experienced talent. They also have the most visible pathway to dominating the ultra-valuable U.S. market, thanks to a planned acquisition of U.S. cannabis company Acreage.All in all, Canopy Growth has significantly differentiated itself from the pack in the cannabis world. As the leader, if pot stocks keep rebounding throughout the rest of the year, CGC stock will lead that rebound. Cronos (CRON)Source: Shutterstock The only other "high quality" cannabis company that has won the multi-billion dollar support of a consumer staples giant is Cronos (NASDAQ:CRON). This unique feature should propel meaningful out-performance in CRON stock in 2020.Cannabis market trends will rebound in 2020 thanks to new products, retail footprint expansion, favorable legislative progress, and international growth, among other things. As those trends rebound, investors will rush back into the marijuana industry like its early 2019 all over again.When investors flocked into the space back then, they did most of that flocking into two names -- Canopy and Cronos -- because those were the smartest and safest investments given their fortified balance sheets, huge investment capability, and tremendous financial support. Of note, Cronos stock outperformed Canopy stock in the first three months of 2019 by a tally of 80% to 60%, mostly thanks to the fact that CRON stock was cheaper than CGC stock (15-times one-year forward sales for CRON, versus 30-times for CGC at the beginning of 2019). * 10 Cheap Stocks to Buy Under $10 In 2020, the same dynamic will repeat. Investors will rush back into the space amid improving fundamentals and trends. They will specifically rush back into the smartest and safest investments in the space, CRON and CGC. And CRON will be the bigger winner, because CRON stock (9-times one-year forward sales) remains way cheaper than CGC stock (14-times one-year forward sales). Aphria (APHA)Although most pot stocks are up big in early 2020, shares of cannabis producer Aphria (NYSE:APHA) are not, mostly because the company reported second quarter numbers in January that missed across the board. Revenues missed estimates, as did profits. And management dramatically cut its full-year guide.Consequently, APHA stock is actually down 1% in 2020, while many of its marijuana peers are up 10% or more.This weakness won't last. It's a gross overreaction to a few headline second quarter misses. Underneath those misses, the numbers were actually pretty good. Revenue growth accelerated sequentially, from up 8% quarter-over-quarter in Q1 to up 9% quarter-over-quarter in Q2. Volume growth also accelerated, and by way more, going from 7% growth in Q2, to 18% growth in Q2. Gross margins reversed course, after dropping from 53% in Q4 to 50% in Q1, and shot back up to 57% in Q2. At the same, Aphria reported a huge sequential increase in adjusted EBITDA after a sequential drop in Q1.In other words, all of the company's important underlying trends improved meaningfully in the second quarter. Revenue, volume, margin, and profit trends all got better.And that's before the launch of new vapes and edibles products. As such, the numbers will only get better in the third and fourth quarters. As they keep improving, investors will push APHA stock way higher, especially considering its relatively depressed valuation base (2-times one-year forward sales). Aurora (ACB)Source: Shutterstock Last, but not least, on this list of marijuana stocks to buy for the big rebound in 2020 is Aurora (NYSE:ACB).Aurora has long been the second-biggest player in the Canadian cannabis market, coming in right behind Canopy in terms of sales, volume, and production capacity. But investors have increasingly expressed concerns over the company's balance sheet and liquidity, as Aurora features one of the worst balance sheets in the cannabis sector and has a major cash burn problem.Ultimately, these concerns have kept ACB stock depressed. These concerns could ease dramatically in 2020. Aurora will launch of suite of edibles and vapes products over the coming months. They should also be opening a ton of new stores.This combination will reignite demand trends at Aurora, and revenue growth rates should start improving. As they do, more favorable supply-demand dynamics will push up margins. Bigger revenues plus bigger margins equals smaller losses. Smaller losses mean less cash burn.As cash burn becomes less of a problem in 2020 (and as the company's improved revenue growth trajectory illuminates a more visible pathway towards profitability), investors will become less concerned about the company's balance sheet and liquidity. The more those concerns fade, the more ACB stock will rally.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 5 Dow Jones Stocks to Buy for 2020 * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure * 3 Tech Stocks to Play Ahead of Earnings The post 4 Marijuana Stocks to Buy for the Big 2020 Rebound appeared first on InvestorPlace.

  • Philip Morris Battles Low Cigarette Volumes, Pricing Aids
    Zacks

    Philip Morris Battles Low Cigarette Volumes, Pricing Aids

    Philip Morris' (PM) performance is bearing adverse impacts of declining cigarette sales volume. However, expansion in RRPs and strong pricing are significant upsides.

  • Coca-Cola (KO) Hits 52-Week High: What's Behind the Rally?
    Zacks

    Coca-Cola (KO) Hits 52-Week High: What's Behind the Rally?

    Coca-Cola's (KO) focus on consumer-centric innovation, solid core brand performance and improved execution in the marketplace bode well.

  • PepsiCo Strengthens Snacking Unit, Product Launches on Track
    Zacks

    PepsiCo Strengthens Snacking Unit, Product Launches on Track

    PepsiCo (PEP) is benefiting from its growing snacks business for a while now. It is also strengthening the Frito-Lay North American with flavorful products.

  • New Cannabis Products Which Could Disrupt the Industry in 2020
    Investopedia

    New Cannabis Products Which Could Disrupt the Industry in 2020

    The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.

  • Canopy Growth: Constellation Brands Remains Unlikely Bidder
    TipRanks

    Canopy Growth: Constellation Brands Remains Unlikely Bidder

    The appetite for Constellation Brands (STZ) buying the rest of Canopy Growth (CGC) appears very low after the company reported another equity loss from the large cannabis investment. If anything, Constellation Brands has huge regrets from making such a large gamble on the Canadian cannabis business near the peak of the market. Canopy Growth jumped to recent highs and Constellation Brands doubling down on Canopy Growth appears very unwise and highly unlikely here.FOMOOne can argue Canopy Growth still trades around $20 due to the inherent put on the stock. This fear of missing out on a Constellation Brands bid for the rest of the company has the stock overvalued, thereby limiting the actual potential of a bid.Constellation Brands owns 35% of the outstanding shares of Canopy Growth and owns warrants to purchase a controlling interest in the cannabis stock with one huge hitch. The warrants have exercise prices far above the current price of Canopy Growth with prices starting at C$50.40 per share.Constellation Brands could save substantial amounts of money by purchasing the rest of Canopy Growth for $30 per share. The latter would still offer a 50% premium above where the stock traded in the prior couple of months.An offer by the wine & spirits company to pay $30 now would cost an additional $7.0 billion.Lack Of FundsThe bigger issue is paying up to a $10+ billion market cap for a money losing company with FY21 (March) revenue expectations of only $583 million. Not only is the price not right here, but also the shareholders of Constellation Brands have no interest in absorbing quarterly EBITDA losses in the $100 million range.Constellation Brands just forecast free cash flows in the $1.5 billion to $1.6 billion range while promising shareholders a substantial portion of those cash flows returned to shareholders via dividends and stock repurchases through 2022. The company already has net debt of $11.5 billion so one shouldn’t foresee another $7 billion spent on the rest of Canopy Growth.The more likely outcome is an aggressive move to snap up a controlling interest (another 15% of the company) in the scenario where the stock dips down to $10. The one hesitation is the company won’t want to absorb the quarterly losses, but investors should be much more comfortable with a Constellation Brands put on the stock somewhere around $10 where a market valuation of $3.5 billion and a large level of cash would provide a more reasonable valuation to pay for the leading cannabis stock.Either way, one needs to watch for the new CEO to implement cost reductions before Constellation Brands could ever build a bigger position. CEO David Klein doesn’t actually start at Canopy Growth until January 14, but he has a mandate to rationalize costs which include curtailing production growth similar to Aurora Cannabis (ACB).Consensus VerdictThe market’s current view on Canopy Growth is a mixed bag, indicating uncertainty as to its prospects. The stock has a Moderate Buy analyst consensus rating with 7 recent "buy" ratings. This is versus 9 "hold" ratings. Furthermore, the $22.59 price target suggests a downside potential of nearly 10% from the current share price. (See Canopy Growth stock analysis at TipRanks)TakeawayThe key investor takeaway is that Canopy Growth isn’t a safe bet here due to the involvement of Constellation Brands. The more likely outcome is further weakness before the wine & spirits company would get more aggressive with snapping up more Canopy Growth shares versus waiting until warrants are exercisable at far higher prices.

  • Is Constellation Brands (STZ) Stock Outpacing Its Consumer Staples Peers This Year?
    Zacks

    Is Constellation Brands (STZ) Stock Outpacing Its Consumer Staples Peers This Year?

    Is (STZ) Outperforming Other Consumer Staples Stocks This Year?

  • GlobeNewswire

    Corona Light® Partners with Multi-Platinum Entertainer Jason Aldean for Summer Leg of 2020 WE BACK TOUR

    First Round of Select Dates on Sale January 24 CHICAGO, Jan. 15, 2020 -- Corona Light, the number one light beer import, will be the lead sponsor behind the summer.

  • 3 Beverage Makers Upping the Game in 2020 With Hard Seltzers
    Zacks

    3 Beverage Makers Upping the Game in 2020 With Hard Seltzers

    Beverage giants have stumbled upon a promising range of hard seltzers, satisfying their need for product diversification as well as meeting consumer preferences.

  • Why the cannabis industry has stalled for more than a year: Morning Brief
    Yahoo Finance

    Why the cannabis industry has stalled for more than a year: Morning Brief

    Top news and what to watch in the markets on Tuesday, January 14, 2020.

  • Wall Street Pros: These 3 Stocks Have Over 25% Upside Potential
    TipRanks

    Wall Street Pros: These 3 Stocks Have Over 25% Upside Potential

    Investors are always on the lookout for stocks poised to deliver hefty returns. While it’s true anyone can measure a stock’s potential by themselves, as in any field, the pros probably have the best tools at hand to assess the choices the market presents.This is where we turn to the analysts on the Street. Some of the best amongst them are currently employed by famed investment firm RBC Capital, as the company sits at the top of the heap of TipRanks’ Top Performing Research Firms.The company, like many in the industry, begins a new year by reassessing the future potential of stocks under its coverage.With this in mind, we decided to take a look at three tickers the investment firm thinks have the potential to take off in 2020. All currently have Buy consensus ratings from the Street and all, according to RBC analysts, have the potential for gains in the magnitude of at least 25% in the year ahead. Let’s check them out.Constellation Brands (STZ)Cannabis stocks took a heavy beating in 2019, with some companies losing a significant amount of value along the way (Tilray, Aurora and Cronos come to mind). Though not strictly a cannabis stock, with its main business driven by the alcoholic beverage industry, Constellation’s massive investment in Canopy Growth, which boasts the largest market cap among Canadian cannabis producers, has positioned it at the forefront of the struggling pot industry.Despite Canopy’s plethora of struggles last year (consecutive quarters of disappointing results, CEO Bruce Linton being removed and replaced with a Constellation appointment), Constellation’s recent F3Q20 report beat expectations on most fronts. Sales of $2 billion beat the estimate’s $1.95 billion. More impressively, EPS came in at $2.14, beating the consensus’s call of $1.84. The most cheer was provided by the company’s beer business, with Constellation’s Modelo Especial brand up by almost 15%, and cementing itself as the fourth-largest beer brand in the US. The company also raised its guidance of EPS for the whole year, too, from $9-$9.20 up to $9.45-$9.55.The positive print has RBC’s Nik Modi betting on STZ. Modi reiterated an Outperform rating on the stock alongside a price target of $250, which implies 32% upside potential from current levels. (To watch Modi’s track record, click here)The 5-star analyst said, “The beer business is fine and should benefit from the Corona Seltzer launch (expected beginning of FY'21 - March 2020). W&S remains messy due to the divestiture, but there are some green shoots that suggest the portfolio will be in a better place post-divestiture. Canopy is still an overhang, but with David Klein in place, we think costs will come under control. All in all, a lot of noise, but we are nearing visibility into 2021 earnings power.”The Street is currently split down the middle with regards to the alcohol producer’s prospects. 6 Buys and 6 Hold ratings coalesce into a Moderate Buy consensus rating. The bulls, though, have the edge as the average price target comes in at $223 and indicates potential gains of 18% over the coming months. (See Constellation Brands stock analysis on TipRanks)Nutrien Ltd (NTR)A big name in the agricultural industry, Nutrien was formed in January 2018 following the huge merger of Agrium and PotashCorp. The company is the world’s largest agricultural input retailer and fertilizer producer.Technological advancements are an increasingly important growth catalyst in many different industries, and the agricultural sector is no different. Nutrien has been maneuvering itself into a leading position in what is known as digital agriculture. The company’s digital platform was launched almost 2 years ago and provides farmers with data on climate and weather conditions to assist in the process of planting, fertilizing and harvesting. The platform met with immediate success and it took only 6 months from its launch for more than 50% of the company’s North American retail sales customers to start making use of it.Nutrien has also been busy on the acquisition front, the latest of which was only announced last week. The company agreed to purchase Brazilian Ag retailer Agrosema Comercial Agricola, an important player in the Brazilian agricultural industry. The purchase comes hot on the heels of several other acquisitions since the launch of its digital platform and RBC’s Andrew Wong thinks there is more to come.The analyst said, “We believe the company will continue the roll-up strategy in North America, spending ~$300–500M annually on accretive acquisitions. In Brazil, we expect Nutrien to gradually build up a base through acquisitions that may be priced above typical valuations (due to less natural synergies), but eventually build a business model similar to the highly successful North American business. The Wholesale segment is working on several cost savings and expansion projects that should result in lower potash production costs and higher nitrogen volumes.”To this end, Wong kept his bullish call on Nutrien with an Outperform rating and price target of $60. The figure represents potential gains in the shape of 27%. (To watch Wong’s track record, click here)What side of the field does the Street stand on regarding the fertilizer producer’s potential, then? On the growing side, as it happens. A Strong Buy consensus rating breaks down into 6 Buys and 2 Holds. The average price target comes in at $56.60 and therefore indicates room for growth of another 20%. (See Nutrien stock analysis on TipRanks)Mosaic Co (MOS)A fellow giant in the agricultural industry is the US’s largest producer of potash and phosphate fertilizer, the Mosaic Company.Mosaic had a difficult 2019 with its share price losing almost 25% over the year. Slipping margins, bad weather and the effect of the US and China trade war all played their part in suppressing the share price. The recent easing of the trading tensions saw Mosaic’s stock climb out of the doldrums in December; China is one of the company’s biggest markets and its willingness to buy more US agricultural products is a part of the phase one trade deal, and could provide a boon for US fertilizer producers.Like Nutrien, Mosaic has also been busy in Brazil; in 2018, the company acquired Vale’s Brazil-based phosphate and potash business. By the end of last year it had run-rate synergies of $275 million, with the company targeting a further $200 million EBITDA benefit from the business by the end of 2022.Despite a disappointing 2019, Andrew Wong, who also covers MOS, believes the phosphate markets are “close to bottoming." The analyst further added, “Mosaic provides strong leverage to the potash and phosphate markets, and we believe it would be an ideal investment in a commodity upside scenario. The acquisition of production and distribution assets in Brazil further enhances the company’s exposure to the fastest-growing agriculture market and provides significant synergy potential.”With this in mind, Wong reiterates an Outperform rating on the potash producer, along with a $26 price target, which implies possible upside of 26%.With 6 Buys, 1 Hold and 1 Sell, Mosiac receives a Moderate Buy consensus rating from the Street. If the average price target of $24.13 can be met, investors stand to pocket a 17% over the next 12 months. (See Mosaic stock analysis on TipRanks)

  • Constellation Brands (STZ) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks

    Constellation Brands (STZ) Upgraded to Buy: What Does It Mean for the Stock?

    Constellation Brands (STZ) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Top Beer Stocks for Q1 2020
    Investopedia

    Top Beer Stocks for Q1 2020

    The beer industry is made up of companies specializing in the production of beer, but which also produce other alcoholic and non-alcoholic beverages. Beverages are considered consumer staples and thus the beer industry may be considered a small part of the broader consumer staples sector.

  • Monster Beverage Up More Than 15%: Will the Rally Continue?
    Zacks

    Monster Beverage Up More Than 15%: Will the Rally Continue?

    Monster Beverage's (MNST) momentum in the energy drinks category should continue to drive performance. Also, its efforts to innovate and launch products are encouraging.

  • Growth in Hard Seltzer to Aid Boston Beer Despite High Costs
    Zacks

    Growth in Hard Seltzer to Aid Boston Beer Despite High Costs

    Boston Beer's (SAM) investments in the Truly brand are likely to bolster its position in the fast-growing hard seltzer category. However, costs and margin woes are clouding its growth potential.

  • Zacks

    A Hectic but Positive First Full Week of 2020

    A Hectic but Positive First Full Week of 2020

  • Constellation Brands, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
    Simply Wall St.

    Constellation Brands, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

    Constellation Brands, Inc. (NYSE:STZ) investors will be delighted, with the company turning in some strong numbers...

  • Constellation Brands to spend $40 million to launch Corona hard seltzer in the spring
    MarketWatch

    Constellation Brands to spend $40 million to launch Corona hard seltzer in the spring

    Constellation Brands Inc. said it will make its biggest-ever single-brand investment to launch its Corona brand hard seltzer this spring — $40 million. Corona hard seltzer will come in four flavors: tropical lime, mango, cherry and blackberry lime. Retailers have already made space on the shelves for the new brand, said William Newlands, Constellation’s chief executive officer, who talked about the launch during the Wednesday earnings call.

  • Has the Smoke Finally Cleared for Canopy Growth Stock?
    InvestorPlace

    Has the Smoke Finally Cleared for Canopy Growth Stock?

    Last year, the cannabis trade was an absolute nightmare. Just about every company came under the crush of heavy selling like Cronos Group (NASDAQ:CRON), Tilray (NASDAQ:TLRY) and Aurora Cannabis (NYSE:ACB).Source: Shutterstock The main reason for this? Simply put, the legalization of cannabis in Canada was overhyped. It also did not help that there were problems with getting retail permits and that black market activities got worse.Despite all this, I think much of this has been baked into the valuations. In other words, there are some interesting opportunities for investors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 of the Strangest Stocks Worth Your Time One that is a standout is Canopy Growth (NYSE:CGC) stock. It is a clear leader in the space, with advantages like the following: * The company has roughly $2.7 billion in the bank. This puts CGC in a strong position as funding has been drying up for cannabis operators. * Canopy has leading market share positions - of over 35% -- in Alberta, which is the most developed recreational market in Canada. There are also supply agreements with government agencies in ten Canadian provinces and territories. * The Spectrum Therapeutics medical subsidiary is a major player in the medical cannabis space, with about 75,600 patients. * There is about 5.4 million square feet of licensed capacity in operation in Canada.All in all, Canopy Growth stock has the benefit of tremendous scale, diversification and liquidity. Because of this, it seems like a pretty good bet that - even if the shakeout continues in the industry - the company will be a long-term winner. The Drivers for 2020One of the many dramas for Canopy Growth stock during 2019 was the termination of CEO Bruce Linton. The company's largest shareholder, Constellation Brands (NYSE:STZ), simply got fed up with the losses that were piling.So, the replacement for Linton will take the helm in mid-January. He is David Klein, who has served in senior leadership roles for the past 14 years at STZ. According to the press release:His capabilities include extensive CPG and beverage alcohol industry experience, strong financial orientation, and experience operating in highly regulated markets in the U.S., Canada, Mexico and Europe. David is an experienced strategist with a deep understanding of how to build enduring consumer brands while leveraging operational scale across a dispersed production footprint. He is a strong leader with a proven track record of developing diverse and high performing teams.Yes, these are the kinds of skill sets that will be crucial for the success of Canopy Growth stock. Initially, Klein is likely to focus on streamlining the organization to get on a path to profitability. But in the meantime, there are some catalysts that should help bolster growth.For example, the U.S. market is looking more promising. Because of the Agriculture Improvement Act of 2018, CGC has been able to introduce hemp and CBD offerings into the market (such as the First & Free line). This has been the result of investments in building a supply chain for hemp cultivation, processing and production.And if there is legalization on a federal level in the U.S., Canopy will be positioned to benefit as it has a partnership agreement with Acreage Holdings.That said, the Cannabis 2.0 opportunity is probably the most important catalyst for the company. This has legalized edibles in the Canadian market, which could be worth $2.7 billion based on research from Deloitte.CGC is definitely prepared. Keep in mind that it already has more than 30 SKUs submitted to Health Canada for vapes, chocolates and beverages. Bottom Line on CGC StockSince mid-November, Canopy Growth stock has staged a nice rally, going from $14 to $20. True, given the swirling uncertainty and continued problems in Canada, this gain could prove temporary. For the most part, volatility will probably continue.So, it's still advisable to not be too aggressive with Canopy Growth Stock. But if you have a longer-term perspective on things, I think gradually building a position does make sense right now.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 of the Strangest Stocks Worth Your Time * 7 Stocks to Buy That Trump's Tax Cut Truly Rewarded * 5 Stocks That Could Double in 2020 The post Has the Smoke Finally Cleared for Canopy Growth Stock? appeared first on InvestorPlace.

  • Why Bill Nygren Only Made 27%
    GuruFocus.com

    Why Bill Nygren Only Made 27%

    A discussion of the guru's 4th-quarter commentary Continue reading...